Indivior extends leadership in substance use disorder treatment

8 June 2021

London-listed Indivior (LON: INDV) today announced that it is extending its leadership position in substance use disorder (SUD) treatment by expanding into the under treated cannabis-related disorders, including cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).

Indivior, which makes the opioid addiction treatment Suboxone, among other things, has teamed up with French privately held biotech Aelis Farma that includes an exclusive option and license agreement for the global rights to AEF0117, Aelis' first-in-class synthetic Signaling Specific inhibitor (SSi) engineered to inhibit the cannabinoid type 1 (CB1) receptor (CB1-SSi).

Aelis' lead CB1-SSi compound AEF0117 is a new chemical entity (NCE) with US composition of matter patent expiry in 2033 and a method of use patent extending to 2039.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK